Kim Brown, CEO, Compass Biomedical | Onyx Live | ISCT Dublin 2026
Everyone watches the final cell therapy – far fewer watch what the cells are grown in. Compass Biomedical's Kim Brown on why culture media quietly shapes the product.
Conversations at the leading edge
OnyxLive.
Meet the people moving biotech forward. Interviews from the conference floor and beyond.
Explore the interviewsFrom Onyx Live
Latest conversations
Jason Jones, Head of Global Business Development, Cellular Origins | Onyx Live | ISCT Dublin 2026
Cell and gene therapy can get treatments approved – scaling them is the hard part. Cellular Origins' Jason Jones on automating manufacturing to reach 100,000 patients a year.
Dimitrios Kouroupis, Professor, University of Miami | Onyx Live | ISCT Dublin 2026
Exosomes are "cell therapy without the cells" – and University of Miami's Dimitrios Kouroupis sees these cell-free vesicles reshaping musculoskeletal medicine.
ISCT: Dublin 2026
Back to latest
Kim Brown, CEO, Compass Biomedical | Onyx Live | ISCT Dublin 2026
Everyone watches the final cell therapy – far fewer watch what the cells are grown in. Compass Biomedical's Kim Brown on why culture media quietly shapes the product.
Jason Jones, Head of Global Business Development, Cellular Origins | Onyx Live | ISCT Dublin 2026
Cell and gene therapy can get treatments approved – scaling them is the hard part. Cellular Origins' Jason Jones on automating manufacturing to reach 100,000 patients a year.
Dimitrios Kouroupis, Professor, University of Miami | Onyx Live | ISCT Dublin 2026
Exosomes are "cell therapy without the cells" – and University of Miami's Dimitrios Kouroupis sees these cell-free vesicles reshaping musculoskeletal medicine.
Jon Ellis, CEO, Trenchant BioSystems | Onyx Live | ISCT Dublin 2026
Fewer than 10% of eligible CAR-T patients ever get treated. Trenchant BioSystems CEO Jon Ellis says the bottleneck is no longer the science – it's manufacturing.
Sean Werner, CTO, BioLife Solutions | Onyx Live | ISCT Dublin 2026
Most cell therapies arrive at the patient frozen – and BioLife Solutions CTO Sean Werner says the field still treats what happens after manufacturing as an afterthought.
Augustin de Bettignies, Chief Business Officer, MPC Therapeutics | Onyx Live | ISCT Dublin 2026
Most of cell therapy fixates on the cell's target. MPC Therapeutics' Augustin de Bettignies says its metabolism — what it burns during manufacturing — matters just as much.
Stephen Sullivan, Founder & Managing Director, Lindville Bio | Onyx Live | ISCT Dublin 2026
Most cell therapies don't fail at the finish line – they fail at the start, says iPSC consultant Stephen Sullivan. Why early decisions decide late outcomes.
Jeff Galecke, Managing Partner, i5 BioPartners | Onyx Live | ISCT Dublin 2026
The cell and gene therapy tools companies that scale aren't always the ones with the best technology, says i5 BioPartners' Jeff Galecke – they're the ones that can tell a clear story.
Bruce Levine, Co-inventor of Kymriah, University of Pennsylvania | Onyx Live | ISCT Dublin 2026
Nine years after Kymriah, the first ever CAR-T cell therapy, was approved, around 10,000 patients have been treated. Inside CAR-T’s next decade with co-inventor Bruce Levine.
Miguel Forte, President, ISCT | Onyx Live | ISCT Dublin 2026
Cell and gene therapy is having its golden age, says ISCT President Miguel Forte – and is still in adolescence. Inside the field's reshaping priorities.
Meeting on the Med 2026
Back to latest
Sven Kili, Partner, Saisei Ventures | Onyx Live | Cell & Gene Meeting on the Med 2026
Great science isn't enough to get funded, says investor Sven Kili – only great medicines are. Inside the CGT funding squeeze, and what specialist VCs actually screen for.
Lisa Deschamps, CEO, AviadoBio | Onyx Live | Cell & Gene Meeting on the Med 2026
AviadoBio is running three CNS gene therapy programs and recently announced a capsid partnership with Apertura to take its silencing platform from rare disease into Alzheimer's.
Marion Hitchcock, Managing Director, Gene & Cell Therapies Incubator Berlin | Onyx Live | Cell & Gene Meeting on the Med 2026
In cell and gene therapy, the science is rarely the bottleneck – making it at scale is. Inside the Bayer–Charité incubator betting on Berlin to fix that.
Faraz Ali, CEO, Tenaya Therapeutics | Onyx Live | Cell & Gene Meeting on the Med 2026
Heart disease kills more people than every cancer combined. Inside Tenaya's bet that the precision-medicine playbook oncology pioneered will work on the heart, too.
Bernd Mühlenweg, CBO/CFO, Cellbox Solutions | Onyx Live | Cell & Gene Meeting on the Med 2026
More and more cell types cannot be frozen anymore. If you think about organoids, mixed cultures, artificial tissues – all of those require warm chain logistics.
Sarmitha Sathiamoorthy, President & Founder, AspireBio Consulting | Onyx Live | Cell & Gene Meeting on the Med 2026
In a funding-constrained biotech market, most early-stage teams still try to reinvent the AAV and advanced-therapy CMC playbooks the industry has already solved a dozen times over.
Alberto Santagostino, CEO & President, AGC Biologics | Onyx Live | Cell & Gene Meeting on the Med 2026
That bottleneck has become one of the biggest constraints on the next decade of cell and gene therapy growth, with hundreds of late-stage programs chasing a manufacturing footprint that has not expanded fast enough to match them.
Ali Soleymannezhad, Chief Commercial Officer, Cellares | Onyx Live | Cell & Gene Meeting on the Med 2026
An estimated 450,000 cancer patients were eligible for CAR-T in 2019; that number is projected to hit 2 million by 2029.
Father Kevin FitzGerald, Professor of Medical Humanities, Creighton University | Onyx Live | Cell & Gene Meeting on the Med 2026
A bioethicist with a PhD in molecular genetics and a seat on the Vatican's Pontifical Academy for Life sits in a rare position to bridge the two.
Steffen Thirstrup, Chief Medical Officer, European Medicines Agency | Onyx Live | Cell & Gene Meeting on the Med 2026
Behind every approval sits a medical-safety sign-off that determines whether a one-shot cell or gene therapy reaches European patients.
Josh Schroeder, Chief of Staff, CTI Clinical Trial and Consulting Services | Onyx Live | Cell & Gene Meeting on the Med 2026
Most CROs were built for small-molecule oncology, not for therapies that have to be manufactured fresh per patient and shipped under tight cold-chain windows.
Devyn Smith, CEO, Arbor Biotechnologies | Onyx Live | Cell & Gene Meeting on the Med 2026
Arbor Biotechnologies' CRISPR-based gene editor ABO-101 is being trialled as a one-time in vivo fix, with the redePHine Phase 1/2 study enrolling up to 23 adult and paediatric patients at Mayo Clinic and additional sites in the US, UK and Europe.
Alexander Seyf, CEO, Autolomous | Onyx Live | Cell & Gene Meeting on the Med 2026
Cell and gene therapy manufacturing still runs largely on paper records and disconnected spreadsheets, and unlike a recalled small molecule, a single batch failure on a personalised therapy can cost a patient their life.
Victor Levitsky, CSO, Circio Holding ASA | Onyx Live | Cell & Gene Meeting on the Med 2026
Circular RNA is roughly an order of magnitude more stable than linear mRNA, extending expression of a therapeutic protein from one day to about a week and unlocking dramatically lower dosing of AAV gene therapies.
Lawrence Tallon, CEO, Medicines and Healthcare products Regulatory Agency | Onyx Live | Cell & Gene Meeting on the Med 2026
The MHRA cleared 84 clinical trial applications in its first 60-day window last year – and Lawrence Tallon wants the next 60 days to look nothing like that.
Stephen Majors, Vice President, Global Communications and Investor Relations, Alliance for Regenerative Medicine | Onyx Live | Cell & Gene Meeting on the Med 2026
Over 400 organisations across 25 countries are racing to bring these therapies to patients with otherwise untreatable diseases.
Advanced Therapies 2026
Back to latest
Stuart Lowe, Head of Advanced Therapies, TTP | Onyx Live | Advanced Therapies 2026
A single CAR-T dose still takes up to 33 days to manufacture, at $170,000–$220,000 per batch.
Stuart Curbishley, Chief Development & Manufacturing Officer, adthera bio | Onyx Live | Advanced Therapies 2026
Stuart Curbishley on how adthera bio is tackling the biggest bottleneck in cell and gene therapy: getting therapies manufactured at scale.
Miguel Forte, President, International Society for Cell & Gene Therapy | Onyx Live | Advanced Therapies 2026
Venture investment in cell and gene therapy has crashed by nearly $8 billion since 2021's peak, putting the field's translation to patients at risk.
Alexander Seyf, CEO, Autolomous | Onyx Live | Advanced Therapies 2026
With over 2,000 cell and gene therapies in clinical trials globally, the industry’s reliance on manual, labour-intensive manufacturing is an existential bottleneck.
JPM 2026
Back to latest
Eric Schlumpf, President & CEO, Stuart Therapeutics | Onyx Live | JPM 2026
Stuart Therapeutics is testing the first collagen mimetic peptide for dry eye disease – a novel mechanism that produced Week 1 staining gains vs. vehicle greater than any reported result for an approved therapy in their recent Phase 3.
Marinna Madrid, Co-Founder, Cellino | Onyx Live | JPM 2026
With zero FDA-approved personalised iPSC therapies on the market, the vast majority of patients who could benefit from regenerative treatments still can’t access them.
Brad Sitko, CIO, XOMA Royalty | Onyx Live | JPM 2026
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
Avi Veidman, CEO, Nucleai | Onyx Live | JPM 2026
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will biotech still be relevant in 2030? | Treehill Partners Ep. 3 | JPM 2026
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
Paul Denslow, CEO, Intus Bio | Onyx Live | JPM 2026
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
Mike Cordonnier, CEO, Carlsmed | Onyx Live | JPM 2026
Hundreds of thousands of spine fusions are performed each year, but implant choice is still often limited to standard sizes.
Chris Hall, CEO, Personalis | Onyx Live | JPM 2026
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
Adrian Gottschalk, CEO, Foghorn Therapeutics | Onyx Live | JPM 2026
The machinery that governs gene expression is being targeted to beat cancer.
Nara Daubeney and Piers Daubeney, CEO and Co-Founder, Phaim | Onyx Live | JPM 2026
Millions of T1DM patients worldwide are on lifelong insulin and constant monitoring. But what if we could switch off the immune attack causing the disease?
Daniel Green, CEO, eSpraye | JPM 2026
If the disease is in the lungs, why deliver the drugs everywhere else?
Fabian Gerlinghaus, CEO, Cellares | Onyx Live | JPM 2026
The platform built to cut CAR-T manufacturing costs by ~50% is about to power its first patient dosing.
Stefan Scherer, CEO, 3T Biosciences | JPM 2026
Many biotechs are trying to perfect T cell targeting - but how many have the backing of Sean Parker and Thiel Capital?
How do biotechs select the right clinical trial partners? Treehill Partners Ep. 2 | Onyx Live | JPM 2026
It's sink or swim.
Nick Delmonico, CEO, Strados Labs | Onyx Live | JPM 2026
1 in 5 patients hospitalized with COPD are readmitted within 30 days of discharge - costing the US over $15 billion. But why?
Andrey Doronichev, CEO, OPTIC | Onyx Live | JPM 2026
Agentic AI makes a big splash in biopharma.
Mike Exton, CEO, Lexicon Pharmaceuticals | JPM 2026
A clear message to investors: get in!
How is AI changing biotech diligence? | Treehill Partners Ep. 1 | Onyx Live | JPM 2026
The status quo is over.
Jefferies 2025
Back to latest
Jefferies Healthcare Conference 2025 - Onyx Roundup | London Life Sciences Week 2025
Capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path.
Onyx @ Jefferies: Lubor Gaal, CFO, Circio
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
Onyx @ Jefferies: David Chang, CEO, Allogene
Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).
Onyx @ Jefferies: Jon Rees, CEO, MitoRx
The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
Onyx @ Jefferies: Ali Pashazadeh, CEO, Treehill Partners
"85% of failures are us having failed the molecule, not the molecule having not delivered."
Onyx @ Jefferies: Warner Biddle, CEO, Kyverna Therapeutics
Fresh momentum from Jefferies and a new $150 million non-dilutive financing has extended its runway into 2027.
Onyx @ Jefferies: David Hung, CEO, Nuvation Bio
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
JPM 2025
Back to latest
Adil's JPM Week VLOG
Join me in San Fran as I interview CEOs and reveal what Onyx has in store for readers this year.
Onyx @ Union Square: Colleen Cutcliffe, CEO, Pendulum
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
Onyx @ Union Square: Helmy Eltoukhy, CEO, Guardant Health
Blood tests for cancer are here, and Guardant Health is leading the charge.
Onyx @ Union Square: Mike Exton, CEO, Lexicon Pharmaceuticals
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Onyx @ Union Square: Shankar Musunuri, CEO, Ocugen
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Onyx Studio Sessions
Back to latest
Onyx Studio Sessions: Paula Brown Stafford, CEO, Allucent
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Onyx Studio Sessions: Fabian Gerlinghaus, CEO, Cellares
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Onyx Explains
Back to latest
eSpraye (Pulmonary fibrosis, Dry Powder) - Onyx Analyst
Dr. Adil Ali asks Dr. John Patton (CSO) and Dan Miller (Formulation Development Lead) all about eSpraye's drug pipeline.
How India is leading a cancer revolution
The story of how an Indian biotech startup slashed the cost of CAR-T from $475,000 to just $30,000 and started a revolution in global CAR-T therapy access.
